Effect of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
Assessing the Impact of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
TCI Co., Ltd.
30 participants
Jul 9, 2026
INTERVENTIONAL
Conditions
Summary
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial glycemic management.
Eligibility
Inclusion Criteria3
- Adults aged 18 years or older;
- Fasting blood glucose level < 100 mg/dL;
- Individuals without type 1 or type 2 diabetes.
Exclusion Criteria6
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
- Individuals with chronic gastrointestinal diseases (such as irritable bowel syndrome \[IBS\], inflammatory bowel disease \[IBD\], chronic diarrhea, celiac disease, short bowel syndrome, ulcers, colorectal cancer, etc.), a history of epilepsy or seizures, psychiatric disorders, malignant tumors, endocrine disorders, liver or kidney disease, or other major organic diseases;
- Individuals with a history of gastrointestinal surgery or organ transplantation;
- Individuals who have taken medications or supplements affecting blood glucose or insulin within the past three months;
- Individuals allergic to peanuts or white kidney beans;
- Full-time employees in the same department as the principal investigator, and students directly taught by the principal investigator during the current semester.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
consume two peanut skin extract capsules (200 mg/capsule) with 150 mL water
consume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water
consume 150 mL water
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07705191